IJNS:护士主导的药物自我管理干预对患有多种疾病老年人药物依从性和健康结局的影响

2022-08-30 小文子 MedSci原创

6周的药物自我管理干预显著改善了干预后即刻的药物依从性,表明了短期干预效果。

患有多种疾病的老年人经常被处方多种药物,药物治疗方案复杂,导致药物成本增加、副作用风险高和药物依从性差。International Journal of Nursing Studies杂志发表了一项研究,评价护士主导的药物自我管理干预对患有多种疾病的老年人的药物依从性和健康结局的影响。

研究从中国长沙3个社区卫生服务中心招募了136名参与者,随机分配到护士主导的6周药物自我管理干预组(n = 67))或常规护理组(n = 69)。干预措施包括3次关于药物相关信息、动机和自我管理技能的一对一教育课程和2次电话随访。主要结局是药物依从性。次要结局包括药物自我管理能力、治疗经验、生活质量和医疗保健服务的利用。在基线、干预后和3个月随访时测量了结局。

结果显示,干预后,干预组在用药依从性(β = 1.63,p = 0.034)、用药知识(β = 2.61,p < 0.001)、用药危害信念(β =-1.83,p < 0.001)、用药自我效能 (β = 3.22,p < 0.001)和用药便利性满意度(β = 5.02,p = 0.005)等方面较对照组有显著改善。在3个月随访时,与对照组相比,干预组在用药知识(β = 2.26,p < 0.001)、用药必要性信念(β = 2.68,p = 0.002)和用药顾虑(β =-2.44,p = 0.002)、用药自我效能(β = 1.87,p = 0.015)和用药负担(β =-3.96,p = 0.004)方面的改善显著高于对照组。干预组在3个月随访时药物依从性较基线改善,但组间差异无统计学意义。在两个时间点,均未发现对生活质量和医疗保健服务利用的统计学显著影响。

结果表明,6周的药物自我管理干预显著改善了干预后即刻的药物依从性,表明了短期干预效果。可能需要更长的干预期和持续的随访支持,以持续改善多种疾病老年人药物依从性和健康结局。

原文出处:

Chen Yang, Diana Tze Fan Lee, et al, Effects of a nurse-led medication self-management intervention on medication adherence and health outcomes in older people with multimorbidity: A randomised controlled trial, International Journal of Nursing Studies, 2022, https://doi.org/10.1016/j.ijnurstu.2022.104314.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2032302, encodeId=ec9420323028a, content=<a href='/topic/show?id=69a28e674a6' target=_blank style='color:#2F92EE;'>#药物依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87674, encryptionId=69a28e674a6, topicName=药物依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Wed Oct 12 16:39:20 CST 2022, time=2022-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803854, encodeId=0330180385485, content=<a href='/topic/show?id=bd07e6034df' target=_blank style='color:#2F92EE;'>#管理干预#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76034, encryptionId=bd07e6034df, topicName=管理干预)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sun Feb 12 17:39:20 CST 2023, time=2023-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2112866, encodeId=f23b211286674, content=老年患者的多重用药问题急需解决, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cba5468764, createdName=ms8000001004052089, createdTime=Fri Feb 03 11:43:10 CST 2023, time=2023-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054223, encodeId=02272054223a0, content=<a href='/topic/show?id=82fa2e92623' target=_blank style='color:#2F92EE;'>#健康结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27926, encryptionId=82fa2e92623, topicName=健康结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Mon Apr 24 13:39:20 CST 2023, time=2023-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248104, encodeId=6b331248104d4, content=多病共存是目前老年人的现状,如何提高患者服药依从性是需要解决的问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201029/9e9ae8f59a9841d995d29937fbfcc93a/355e54d06206477bba328056b2a0e88f.jpg, createdBy=31cf5430202, createdName=May2020, createdTime=Fri Sep 09 12:17:40 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242038, encodeId=214f124203845, content=认真学习~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Tue Aug 30 12:57:29 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319369, encodeId=e8481319369f8, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Wed Aug 31 10:39:20 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435103, encodeId=bd8114351030f, content=<a href='/topic/show?id=b3718618000' target=_blank style='color:#2F92EE;'>#自我管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86180, encryptionId=b3718618000, topicName=自我管理)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Aug 31 10:39:20 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242197, encodeId=2f5e124219e23, content=认真学习~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Wed Aug 31 07:04:08 CST 2022, time=2022-08-31, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2032302, encodeId=ec9420323028a, content=<a href='/topic/show?id=69a28e674a6' target=_blank style='color:#2F92EE;'>#药物依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87674, encryptionId=69a28e674a6, topicName=药物依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Wed Oct 12 16:39:20 CST 2022, time=2022-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803854, encodeId=0330180385485, content=<a href='/topic/show?id=bd07e6034df' target=_blank style='color:#2F92EE;'>#管理干预#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76034, encryptionId=bd07e6034df, topicName=管理干预)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sun Feb 12 17:39:20 CST 2023, time=2023-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2112866, encodeId=f23b211286674, content=老年患者的多重用药问题急需解决, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cba5468764, createdName=ms8000001004052089, createdTime=Fri Feb 03 11:43:10 CST 2023, time=2023-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054223, encodeId=02272054223a0, content=<a href='/topic/show?id=82fa2e92623' target=_blank style='color:#2F92EE;'>#健康结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27926, encryptionId=82fa2e92623, topicName=健康结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Mon Apr 24 13:39:20 CST 2023, time=2023-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248104, encodeId=6b331248104d4, content=多病共存是目前老年人的现状,如何提高患者服药依从性是需要解决的问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201029/9e9ae8f59a9841d995d29937fbfcc93a/355e54d06206477bba328056b2a0e88f.jpg, createdBy=31cf5430202, createdName=May2020, createdTime=Fri Sep 09 12:17:40 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242038, encodeId=214f124203845, content=认真学习~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Tue Aug 30 12:57:29 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319369, encodeId=e8481319369f8, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Wed Aug 31 10:39:20 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435103, encodeId=bd8114351030f, content=<a href='/topic/show?id=b3718618000' target=_blank style='color:#2F92EE;'>#自我管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86180, encryptionId=b3718618000, topicName=自我管理)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Aug 31 10:39:20 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242197, encodeId=2f5e124219e23, content=认真学习~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Wed Aug 31 07:04:08 CST 2022, time=2022-08-31, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2032302, encodeId=ec9420323028a, content=<a href='/topic/show?id=69a28e674a6' target=_blank style='color:#2F92EE;'>#药物依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87674, encryptionId=69a28e674a6, topicName=药物依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Wed Oct 12 16:39:20 CST 2022, time=2022-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803854, encodeId=0330180385485, content=<a href='/topic/show?id=bd07e6034df' target=_blank style='color:#2F92EE;'>#管理干预#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76034, encryptionId=bd07e6034df, topicName=管理干预)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sun Feb 12 17:39:20 CST 2023, time=2023-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2112866, encodeId=f23b211286674, content=老年患者的多重用药问题急需解决, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cba5468764, createdName=ms8000001004052089, createdTime=Fri Feb 03 11:43:10 CST 2023, time=2023-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054223, encodeId=02272054223a0, content=<a href='/topic/show?id=82fa2e92623' target=_blank style='color:#2F92EE;'>#健康结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27926, encryptionId=82fa2e92623, topicName=健康结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Mon Apr 24 13:39:20 CST 2023, time=2023-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248104, encodeId=6b331248104d4, content=多病共存是目前老年人的现状,如何提高患者服药依从性是需要解决的问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201029/9e9ae8f59a9841d995d29937fbfcc93a/355e54d06206477bba328056b2a0e88f.jpg, createdBy=31cf5430202, createdName=May2020, createdTime=Fri Sep 09 12:17:40 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242038, encodeId=214f124203845, content=认真学习~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Tue Aug 30 12:57:29 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319369, encodeId=e8481319369f8, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Wed Aug 31 10:39:20 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435103, encodeId=bd8114351030f, content=<a href='/topic/show?id=b3718618000' target=_blank style='color:#2F92EE;'>#自我管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86180, encryptionId=b3718618000, topicName=自我管理)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Aug 31 10:39:20 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242197, encodeId=2f5e124219e23, content=认真学习~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Wed Aug 31 07:04:08 CST 2022, time=2022-08-31, status=1, ipAttribution=)]
    2023-02-03 ms8000001004052089

    老年患者的多重用药问题急需解决

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2032302, encodeId=ec9420323028a, content=<a href='/topic/show?id=69a28e674a6' target=_blank style='color:#2F92EE;'>#药物依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87674, encryptionId=69a28e674a6, topicName=药物依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Wed Oct 12 16:39:20 CST 2022, time=2022-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803854, encodeId=0330180385485, content=<a href='/topic/show?id=bd07e6034df' target=_blank style='color:#2F92EE;'>#管理干预#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76034, encryptionId=bd07e6034df, topicName=管理干预)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sun Feb 12 17:39:20 CST 2023, time=2023-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2112866, encodeId=f23b211286674, content=老年患者的多重用药问题急需解决, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cba5468764, createdName=ms8000001004052089, createdTime=Fri Feb 03 11:43:10 CST 2023, time=2023-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054223, encodeId=02272054223a0, content=<a href='/topic/show?id=82fa2e92623' target=_blank style='color:#2F92EE;'>#健康结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27926, encryptionId=82fa2e92623, topicName=健康结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Mon Apr 24 13:39:20 CST 2023, time=2023-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248104, encodeId=6b331248104d4, content=多病共存是目前老年人的现状,如何提高患者服药依从性是需要解决的问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201029/9e9ae8f59a9841d995d29937fbfcc93a/355e54d06206477bba328056b2a0e88f.jpg, createdBy=31cf5430202, createdName=May2020, createdTime=Fri Sep 09 12:17:40 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242038, encodeId=214f124203845, content=认真学习~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Tue Aug 30 12:57:29 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319369, encodeId=e8481319369f8, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Wed Aug 31 10:39:20 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435103, encodeId=bd8114351030f, content=<a href='/topic/show?id=b3718618000' target=_blank style='color:#2F92EE;'>#自我管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86180, encryptionId=b3718618000, topicName=自我管理)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Aug 31 10:39:20 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242197, encodeId=2f5e124219e23, content=认真学习~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Wed Aug 31 07:04:08 CST 2022, time=2022-08-31, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2032302, encodeId=ec9420323028a, content=<a href='/topic/show?id=69a28e674a6' target=_blank style='color:#2F92EE;'>#药物依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87674, encryptionId=69a28e674a6, topicName=药物依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Wed Oct 12 16:39:20 CST 2022, time=2022-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803854, encodeId=0330180385485, content=<a href='/topic/show?id=bd07e6034df' target=_blank style='color:#2F92EE;'>#管理干预#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76034, encryptionId=bd07e6034df, topicName=管理干预)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sun Feb 12 17:39:20 CST 2023, time=2023-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2112866, encodeId=f23b211286674, content=老年患者的多重用药问题急需解决, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cba5468764, createdName=ms8000001004052089, createdTime=Fri Feb 03 11:43:10 CST 2023, time=2023-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054223, encodeId=02272054223a0, content=<a href='/topic/show?id=82fa2e92623' target=_blank style='color:#2F92EE;'>#健康结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27926, encryptionId=82fa2e92623, topicName=健康结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Mon Apr 24 13:39:20 CST 2023, time=2023-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248104, encodeId=6b331248104d4, content=多病共存是目前老年人的现状,如何提高患者服药依从性是需要解决的问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201029/9e9ae8f59a9841d995d29937fbfcc93a/355e54d06206477bba328056b2a0e88f.jpg, createdBy=31cf5430202, createdName=May2020, createdTime=Fri Sep 09 12:17:40 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242038, encodeId=214f124203845, content=认真学习~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Tue Aug 30 12:57:29 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319369, encodeId=e8481319369f8, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Wed Aug 31 10:39:20 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435103, encodeId=bd8114351030f, content=<a href='/topic/show?id=b3718618000' target=_blank style='color:#2F92EE;'>#自我管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86180, encryptionId=b3718618000, topicName=自我管理)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Aug 31 10:39:20 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242197, encodeId=2f5e124219e23, content=认真学习~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Wed Aug 31 07:04:08 CST 2022, time=2022-08-31, status=1, ipAttribution=)]
    2022-09-09 May2020

    多病共存是目前老年人的现状,如何提高患者服药依从性是需要解决的问题

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2032302, encodeId=ec9420323028a, content=<a href='/topic/show?id=69a28e674a6' target=_blank style='color:#2F92EE;'>#药物依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87674, encryptionId=69a28e674a6, topicName=药物依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Wed Oct 12 16:39:20 CST 2022, time=2022-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803854, encodeId=0330180385485, content=<a href='/topic/show?id=bd07e6034df' target=_blank style='color:#2F92EE;'>#管理干预#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76034, encryptionId=bd07e6034df, topicName=管理干预)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sun Feb 12 17:39:20 CST 2023, time=2023-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2112866, encodeId=f23b211286674, content=老年患者的多重用药问题急需解决, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cba5468764, createdName=ms8000001004052089, createdTime=Fri Feb 03 11:43:10 CST 2023, time=2023-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054223, encodeId=02272054223a0, content=<a href='/topic/show?id=82fa2e92623' target=_blank style='color:#2F92EE;'>#健康结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27926, encryptionId=82fa2e92623, topicName=健康结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Mon Apr 24 13:39:20 CST 2023, time=2023-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248104, encodeId=6b331248104d4, content=多病共存是目前老年人的现状,如何提高患者服药依从性是需要解决的问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201029/9e9ae8f59a9841d995d29937fbfcc93a/355e54d06206477bba328056b2a0e88f.jpg, createdBy=31cf5430202, createdName=May2020, createdTime=Fri Sep 09 12:17:40 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242038, encodeId=214f124203845, content=认真学习~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Tue Aug 30 12:57:29 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319369, encodeId=e8481319369f8, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Wed Aug 31 10:39:20 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435103, encodeId=bd8114351030f, content=<a href='/topic/show?id=b3718618000' target=_blank style='color:#2F92EE;'>#自我管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86180, encryptionId=b3718618000, topicName=自我管理)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Aug 31 10:39:20 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242197, encodeId=2f5e124219e23, content=认真学习~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Wed Aug 31 07:04:08 CST 2022, time=2022-08-31, status=1, ipAttribution=)]
    2022-08-30 xulv123

    认真学习~~

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2032302, encodeId=ec9420323028a, content=<a href='/topic/show?id=69a28e674a6' target=_blank style='color:#2F92EE;'>#药物依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87674, encryptionId=69a28e674a6, topicName=药物依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Wed Oct 12 16:39:20 CST 2022, time=2022-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803854, encodeId=0330180385485, content=<a href='/topic/show?id=bd07e6034df' target=_blank style='color:#2F92EE;'>#管理干预#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76034, encryptionId=bd07e6034df, topicName=管理干预)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sun Feb 12 17:39:20 CST 2023, time=2023-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2112866, encodeId=f23b211286674, content=老年患者的多重用药问题急需解决, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cba5468764, createdName=ms8000001004052089, createdTime=Fri Feb 03 11:43:10 CST 2023, time=2023-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054223, encodeId=02272054223a0, content=<a href='/topic/show?id=82fa2e92623' target=_blank style='color:#2F92EE;'>#健康结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27926, encryptionId=82fa2e92623, topicName=健康结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Mon Apr 24 13:39:20 CST 2023, time=2023-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248104, encodeId=6b331248104d4, content=多病共存是目前老年人的现状,如何提高患者服药依从性是需要解决的问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201029/9e9ae8f59a9841d995d29937fbfcc93a/355e54d06206477bba328056b2a0e88f.jpg, createdBy=31cf5430202, createdName=May2020, createdTime=Fri Sep 09 12:17:40 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242038, encodeId=214f124203845, content=认真学习~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Tue Aug 30 12:57:29 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319369, encodeId=e8481319369f8, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Wed Aug 31 10:39:20 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435103, encodeId=bd8114351030f, content=<a href='/topic/show?id=b3718618000' target=_blank style='color:#2F92EE;'>#自我管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86180, encryptionId=b3718618000, topicName=自我管理)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Aug 31 10:39:20 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242197, encodeId=2f5e124219e23, content=认真学习~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Wed Aug 31 07:04:08 CST 2022, time=2022-08-31, status=1, ipAttribution=)]
    2022-08-31 fyxzlh
  8. [GetPortalCommentsPageByObjectIdResponse(id=2032302, encodeId=ec9420323028a, content=<a href='/topic/show?id=69a28e674a6' target=_blank style='color:#2F92EE;'>#药物依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87674, encryptionId=69a28e674a6, topicName=药物依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Wed Oct 12 16:39:20 CST 2022, time=2022-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803854, encodeId=0330180385485, content=<a href='/topic/show?id=bd07e6034df' target=_blank style='color:#2F92EE;'>#管理干预#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76034, encryptionId=bd07e6034df, topicName=管理干预)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sun Feb 12 17:39:20 CST 2023, time=2023-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2112866, encodeId=f23b211286674, content=老年患者的多重用药问题急需解决, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cba5468764, createdName=ms8000001004052089, createdTime=Fri Feb 03 11:43:10 CST 2023, time=2023-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054223, encodeId=02272054223a0, content=<a href='/topic/show?id=82fa2e92623' target=_blank style='color:#2F92EE;'>#健康结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27926, encryptionId=82fa2e92623, topicName=健康结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Mon Apr 24 13:39:20 CST 2023, time=2023-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248104, encodeId=6b331248104d4, content=多病共存是目前老年人的现状,如何提高患者服药依从性是需要解决的问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201029/9e9ae8f59a9841d995d29937fbfcc93a/355e54d06206477bba328056b2a0e88f.jpg, createdBy=31cf5430202, createdName=May2020, createdTime=Fri Sep 09 12:17:40 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242038, encodeId=214f124203845, content=认真学习~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Tue Aug 30 12:57:29 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319369, encodeId=e8481319369f8, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Wed Aug 31 10:39:20 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435103, encodeId=bd8114351030f, content=<a href='/topic/show?id=b3718618000' target=_blank style='color:#2F92EE;'>#自我管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86180, encryptionId=b3718618000, topicName=自我管理)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Aug 31 10:39:20 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242197, encodeId=2f5e124219e23, content=认真学习~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Wed Aug 31 07:04:08 CST 2022, time=2022-08-31, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=2032302, encodeId=ec9420323028a, content=<a href='/topic/show?id=69a28e674a6' target=_blank style='color:#2F92EE;'>#药物依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87674, encryptionId=69a28e674a6, topicName=药物依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Wed Oct 12 16:39:20 CST 2022, time=2022-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803854, encodeId=0330180385485, content=<a href='/topic/show?id=bd07e6034df' target=_blank style='color:#2F92EE;'>#管理干预#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76034, encryptionId=bd07e6034df, topicName=管理干预)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sun Feb 12 17:39:20 CST 2023, time=2023-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2112866, encodeId=f23b211286674, content=老年患者的多重用药问题急需解决, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cba5468764, createdName=ms8000001004052089, createdTime=Fri Feb 03 11:43:10 CST 2023, time=2023-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054223, encodeId=02272054223a0, content=<a href='/topic/show?id=82fa2e92623' target=_blank style='color:#2F92EE;'>#健康结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27926, encryptionId=82fa2e92623, topicName=健康结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Mon Apr 24 13:39:20 CST 2023, time=2023-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248104, encodeId=6b331248104d4, content=多病共存是目前老年人的现状,如何提高患者服药依从性是需要解决的问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201029/9e9ae8f59a9841d995d29937fbfcc93a/355e54d06206477bba328056b2a0e88f.jpg, createdBy=31cf5430202, createdName=May2020, createdTime=Fri Sep 09 12:17:40 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242038, encodeId=214f124203845, content=认真学习~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Tue Aug 30 12:57:29 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319369, encodeId=e8481319369f8, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Wed Aug 31 10:39:20 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435103, encodeId=bd8114351030f, content=<a href='/topic/show?id=b3718618000' target=_blank style='color:#2F92EE;'>#自我管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86180, encryptionId=b3718618000, topicName=自我管理)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Aug 31 10:39:20 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242197, encodeId=2f5e124219e23, content=认真学习~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Wed Aug 31 07:04:08 CST 2022, time=2022-08-31, status=1, ipAttribution=)]
    2022-08-31 xulv123

    认真学习~~

    0

相关资讯

J Nurs Manag:近50%的护士经历过职场暴力

职场暴力在我国护士中很常见。良好的工作条件、总体幸福感和积极应对可能有助于预防职场暴力伤害。

深圳护士有处方权,开国内医改先河

在深圳特区,医疗系统传出一个大消息——护士将拥有处方权!

因不满医院频繁考试,这名护士把医院投诉了!

因不满医院频繁考试,这名护士把医院投诉了!

Nurs Outlook:到底是什么原因导致护士工作混乱?

护士工作流程动荡的两个主要来源是沟通和工作量。

J Nurs Manag:护士毕业4年的工作状况及相关因素

研究阐述了护士经历换工作后重新就业的个人的工作条件和满意度。